Method: This was an analysis that compared outcomes among patients who received chidamide CHOP on a clinical trial vs. historical controls who received CHOP alone, enrolling a total of sixty-six treatment-naive AITL patients between April 2014 and November 2022. Among them...
In Apr. 2024, Chidamide in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) was approved in China for the treatment of therapy-naive patients with MYC- and BCL2-positive diffuse large B-cell lymphoma (DLBCL). Exploration of Other Indications Worldwide...
Application of chidamide in combination with R-CHOP, and drug combination 发明人: LU Xianping;ZHAO Weili;FU Xin;XU Pengpeng;LIU Ting 申请人: Shenzhen Chipscreen Biosciences Co LtdRui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine 申请日期: 2019-11-18 申请公布日期:...
to mesenchymal transition, which are hallmarks of treatment resistance, tumor cell metastasis and recurrence. Chidamide was approved onDecember 23rdof 2014 by China Food and Drug Administration (CFDA) for recurrent and refractory peripheral T...
"Chidamide is the first new molecular entity discovered and developed by Chipscreen scientists inChina. The CFDA's decision to approval the world first orally administrated selective HDACi for PTCLs is an important validation of the drug's therapeutic potential for this urgent medical need for Chine...
Patient #1 was a 57-year-old man who had become resistant from 6 times rituximab plus CHOP treatment; patient #2 was a 63-year-old man who was diagnosed as non-hodgkin’s lymphoma; patient #3 was a DLBCL patient who had relapsed from 3 times rituximab plus CHOP treatment. All primary...
The present invention provides an application of Chidamide in combination with R-CHOP in preparing a drug used for treating B-cell lymphoma, and also provides a drug comprising Chidamide and R-CHOP. Chidamide in combination with R-CHOP has a synergistic therapeutic effect on B-cell lymphoma.LU ...
The present application provides an application of Chidamide in combination with R-CHOP in preparing a drug used for treating B-cell lymphoma, and also provides a drug comprising Chidamide and R-CHOP. Chidamide in combination with R-CHOP has a synergistic therapeutic effect on B-cell lymphoma....
(57.1%) achieving complete response or unconfirmed complete response.The estimated median progression-free survival was 14.0 months.In summary,we chose chidamide 30 mg as the recommended dose for phase 2.Conclusions:The addition of chidamide to standard CHOP chemotherapy was tolerable with promising ...
The present invention provides an application of Chidamide in combination with R-CHOP in preparing a drug used for treating B-cell lymphoma, and also provides a drug comprising Chidamide and R-CHOP. Chidamide in combination with R-CHOP has a synergistic therapeutic effect on B-cell lymphoma.LU,...